Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 10,000 shares at $16.18 ($162K) on 2024-02-01, disclosed to the SEC on 2024-02-05.
Open-market sale of $162k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.18 | 9,300 | $150K | 92.7% |
| 2 | $16.81 | 700 | $12K | 7.3% |
| Total | $16.22 avg | 10,000 | $162K | 100% |
| Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |
| KALV | SELL | 2023-08-21 | $319K | — | Filing → |